Enalten

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enalten

Enalten is a synthetic, prescription-only medicine primarily used as an antihypertensive agent. Its purpose is to help manage the mechanical stress placed on the heart and circulatory system.

Property Description
Active Ingredient Enalapril maleate
Form Oral preparation (Tablet)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose Systemic lowering of blood pressure
Origin Synthetic compound

What Type of Medicine is Enalten?

Enalten is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, which places it among the clinically recognized treatments that modulate the body’s Renin-Angiotensin-Aldosterone System (RAAS). This specific, systemic action is a key differentiating factor from other cardiovascular medications, providing a targeted approach to managing circulatory load.

Active Ingredient and Pharmaceutical Form

Its active ingredient is Enalapril maleate, which is formulated for oral administration as a tablet. Enalapril is specifically known as a prodrug and must be metabolized by the body into its active form, Enalaprilat, to produce its therapeutic effect. The tablet typically contains Enalapril maleate as the single therapeutic component (monotherapy), making its composition straightforward and reliable for continuous dose-dependent use.

General Purpose and Core Therapeutic Benefit

The general therapeutic purpose of Enalten is the systemic lowering of blood pressure. This action is accomplished by promoting the relaxation and widening of the blood vessels, which reduces the mechanical resistance against which the heart must pump blood. The core benefit of this mechanism is a decreased workload on the heart muscle and reduced strain on the arterial walls, supporting overall long-term cardiovascular stability.

Regulatory References

  1. World Health Organization, Essential Medicines List

What side effects are possible with Enalten?

Possible Side Effects and Safety Information for Enalten (Enalapril Maleate)

Serious Adverse Reactions and Restrictions

Boxed Warning: The use of Enalten during pregnancy is contraindicated. Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus, particularly during the second and third trimesters. Treatment must be discontinued immediately upon detection of pregnancy.

Clinically Significant Reactions:

  • Angioedema: Swelling of the face, extremities, lips, tongue, glottis, and/or larynx, which can be fatal due to airway obstruction. Angioedema can occur at any time during treatment. This risk is higher in Black patients and those with a history of swelling.
  • Hypotension: Symptomatic low blood pressure, especially after the initial dose or in volume-depleted patients.
  • Hyperkalemia: Elevated potassium levels in the blood.
  • Renal Function Deterioration: Increased risk of renal impairment or failure, particularly in patients with pre-existing renal disease.

Contraindications:

  • History of angioedema related to previous ACE inhibitor treatment, or hereditary/idiopathic angioedema.
  • Concomitant use with aliskiren in patients with diabetes or with a GFR <60 mL/min/1.73 m^2.
  • Concomitant use with a neprilysin inhibitor (e.g., sacubitril/valsartan); a 36-hour wash-out period is required between administrations.

Summary of Adverse Reactions by Frequency

Frequency Classification Key Adverse Reactions (by System-Organ Class)
Very Common (ge 10%) Cough, Dizziness, Blurred vision, Asthenia (lack of strength).
Common (ge 1% to <10%) Headache, Hypotension, Fatigue, Chest pain, Nausea, Diarrhea, Rash, Hyperkalemia, Depression.
Uncommon (ge 0.1% to <1%) Vertigo, Paresthesia, Renal failure, Angioedema, Insomnia.

Safety Profile Context

The safety profile is primarily characterized by risks associated with the drug's mechanism on the renin-angiotensin system, necessitating close monitoring for severe, potentially life-threatening events such as angioedema and significant effects on blood pressure and kidney function. Official regulatory documents define clear restrictions for use in pregnancy and against co-administration with other specific cardiovascular drug classes due to additive risks. This framework establishes the necessary safety surveillance protocols during treatment.

Overdose and Emergency Response

The primary clinical sign of an Enalten overdose, documented in official regulatory sources, is the severe and exaggerated extension of its effect: profound hypotension (dangerously low blood pressure). This is often accompanied by associated manifestations such as dizziness, faintness, and changes in heart rate (tachycardia or bradycardia).

Overdose requires immediate medical attention due to the potential for life-threatening outcomes. These include progression to circulatory shock, metabolic issues like Hyperkalemia (high serum potassium), and the risk of Angioedema (swelling of the face, tongue, or throat), which can compromise the airway. Patients with existing renal impairment or those who are volume-depleted are noted to be at increased risk for excessive hypotension.

No specific antidote is known for Enalapril maleate. Official management is strictly symptomatic and supportive, involving placing the patient in a supine position and administering intravenous saline to counteract hypotension. Hemodialysis is documented as an effective procedural measure for removing the active metabolite, Enalaprilat. Observation for a minimum of four to six hours, with monitoring of renal function and serum electrolytes, is required even for asymptomatic patients.

Therapeutic Uses of Enalten

What Enalten Treats: Main Uses and Benefits

Enalten (Enalapril maleate) is a foundational, long-term medicine that is commonly used to help manage significant cardiovascular and renal health challenges. Therapeutic domains that are considered relevant for this medication include managing symptoms of heart failure, addressing chronic high blood pressure (Hypertension), and sometimes providing supportive treatment for kidney disease related to diabetes.

The medicine is commonly used in conditions such as heart failure, where it helps relieve symptoms associated with cardiac overload. It provides supportive relief for challenging manifestations such as shortness of breath (dyspnea) and excessive fatigue. By consistently lowering pressure, Enalten provides the key therapeutic benefit of supporting the goal of lowering the risk of major cardiovascular events, offering essential support for overall cardiovascular stability.

“The management of this medication provides supportive relief against the systemic strain associated with chronic high pressure.”


Quick Fact: Relief for Asymptomatic Systemic Strain

Enalten is commonly applied in contexts involving organ-specific functional stress, particularly in patients with diabetes or other co-morbidities. This preventative benefit is considered relevant for supporting the goal of maintaining functional stability over time.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Enalten (Enalapril maleate) eligibility is determined by specific population characteristics and medical conditions, as defined in official regulatory documents.

Contraindicated Populations (Must Not Use)

Enalten is contraindicated for patients with a history of angioedema related to any previous ACE inhibitor use, or those with hereditary or idiopathic angioedema. It is also prohibited for patients in the second and third trimesters of pregnancy. Use is strictly forbidden if the patient is taking medication containing aliskiren and also has diabetes or renal impairment. Furthermore, the medicine must not be taken within 36 hours before or after taking a neprilysin inhibitor like sacubitril/valsartan.

Age-Related Eligibility Rules

Age Group Eligibility Status
Adults Approved for all labeled indications (e.g., hypertension, heart failure).
Children Approved for hypertension in patients ge 1 month to 16 years. Contraindicated in pediatric patients with severe renal impairment (GFR <30 mL/min/1.73 m^2).
Infants Not recommended in infants le 1 month of age.
Older Adults Use requires caution, and dose is adjusted according to renal function status.

Pregnancy and Lactation Status

Use is contraindicated during the second and third trimesters of pregnancy and is not recommended during the first trimester. Use while breastfeeding is generally not recommended, especially for newborns and premature infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Enalten (Enalapril maleate) has officially documented interaction patterns that enforce specific administration constraints, as defined in regulatory labeling.

Official Restrictions and Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril-containing products) is strictly contraindicated due to the high risk of angioedema. A mandatory 36-hour separation is required when switching between Enalten and a neprilysin inhibitor. Concomitant use with Aliskiren is also contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment. Furthermore, Enalten use is restricted during specific medical procedures, including dialysis with certain high-flux membranes and apheretic treatments using a Protein A column.

Pharmacodynamic and Exposure Interactions

Combining Enalten with Potassium-Sparing Diuretics (e.g., Spironolactone) or Potassium Supplements may cause hyperkalemia (elevated serum potassium) due to additive effects on electrolyte levels. The addition of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors, increases the risk of deterioration of renal function, a risk which is noted to be heightened in the elderly. Co-administration with Lithium is documented to increase its serum concentration due to reduced clearance.

Mechanism of Action

Enalten is a fully human monoclonal IgG2 antibody that specifically binds to Receptor Activator of Nuclear Factor kappaB Ligand (RANKL). It functions as an inhibitor of the RANKL-RANK interaction. This binding prevents soluble and membrane-bound RANKL from activating its receptor, RANK, which is expressed on the surface of pre-osteoclasts and mature osteoclasts.

The inhibition of this interaction reduces the differentiation, activation, and survival of osteoclasts. This process directly modulates the osteoclastogenic pathway, leading to a functional decrease in the cell-mediated breakdown of mineralized bone matrix (bone resorption).

Consequently, the net effect of Enalten's action is a sustained decrease in bone resorption activity. This ultimately shifts the balance of bone remodeling toward osteoblastic activity (bone formation), resulting in increased bone mineral density.

Dosage and Administration Information

How Enalten is Used: Official Administration Guidelines

Enalten (Enalapril maleate) is a medication whose use is strictly defined by guidelines to ensure appropriate administration. The official instructions focus on the prescribed routes, specific dosing schedules, and required conditions for intake, avoiding any information related to therapeutic effects or safety.

Official Routes and Forms

Enalten is approved primarily for Oral Administration as a tablet. The active ingredient, Enalapril maleate, is available in standard oral strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg tablets, which may be taken with or without food. In specific clinical settings, the active form, Enalaprilat, may be administered intravenously.

Standard Dosing and Titration Schedules

Official use involves an initial dose, which is systematically increased (titrated) to a target maintenance level. The maximum recommended daily dose for the tablet form is 40 mg.

Indication Initial Dose (Adults) Maximum Daily Dose
Hypertension 5 mg once daily 40 mg
Heart Failure 2.5 mg once or twice daily 40 mg (divided doses)

The dose for conditions like Heart Failure is typically titrated (gradually increased) over a 2 to 4 week period to reach the maintenance dose, provided the increase is well-tolerated.

Population-Specific Administration

Guidelines outline specific adjustments for certain patient groups:

  • Renal Impairment: Patients with significant kidney function impairment (Creatinine Clearance less than or equal to 30 mL/min) should begin with a reduced dose of 2.5 mg once daily.
  • Initial Supervision: The first dose, especially when initiating therapy for Heart Failure, is recommended to be administered under close medical supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Enalten

The information presented here summarizes the type and scope of clinical research available for Enalapril maleate, drawing only from authorized regulatory and scientific sources. The purpose is to describe what the studies explored and what their findings describe patterns observed in the studies, without providing any medical or therapeutic advice.


Evidence for Use in Chronic High Blood Pressure (Hypertension)

The study landscape for chronic high blood pressure includes large-scale, long-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews and Meta-analyses. These studies were studied for outcomes related to physiological strain or stress on the cardiovascular system.

The research examined changes in blood pressure measurements over defined time intervals against a control or comparator. Research also was studied for outcomes reflecting daily functioning or activity level, and examined outcomes related to major cardiovascular events, such as the reporting of strokes or heart attacks. Some research indicates that the data show patterns related to a smaller average blood pressure change in certain demographics when used without other agents.


Evidence for Use in the Heart Failure Spectrum

Research into Enalapril maleate's evaluation for conditions marked by functional limitations of the heart is categorized by two patient groups: those with symptoms and those who are asymptomatic but show early signs of heart dysfunction.

The body of evidence in symptomatic heart failure involves landmark, long-term RCTs. These studies monitored outcomes related to all-cause mortality and hospital admission frequency associated with heart failure. For patients without symptoms, large, placebo-controlled prevention trials explored the rate of conversion to symptomatic heart failure. Research focusing on Heart Failure with Preserved Ejection Fraction (HFpEF) the data are still emerging and findings were mixed regarding key functional outcomes.


What the Research Landscape Leaves Uncertain

The evidence quality varies across studies. In areas like heart failure, more recent therapeutic options have been introduced, and comparative evidence is lacking regarding outcomes related to all contemporary therapies, meaning the certainty remains low when describing differences against non-tested drugs. Data for certain groups remain insufficient, specifically for patients with severe pre-existing renal impairment or a large body of dedicated evidence in patients with Type 1 diabetes.

Frequently Asked Questions (FAQ)

Common questions about Enalten (FAQ)

Q: How long does it usually take to feel the effects of Enalten?

A: According to official product information, the onset of action for Enalaprilat, which is the active form of Enalten, typically occurs within 15 minutes of administration. The maximum effect is generally observed within one to four hours. The therapeutic action of a single dose has been observed to last for several hours in most patients.

Q: Can Enalten be stopped suddenly?

A: Studies indicate that the abrupt discontinuation of Enalapril has not been associated with a rapid rebound increase in blood pressure. Official information from regulatory documents can provide details regarding stopping treatment.

Q: Is it common to feel tired when taking Enalten?

A: Yes, official safety information lists feelings of fatigue and asthenia (a medical term for a lack of strength or energy) as very common or common adverse reactions in studies. Asthenia is reported as a very common reaction, and fatigue is listed as a common reaction.

Q: Is Enalten safe for older adults (seniors)?

A: Official documentation indicates that use in older adults may necessitate a cautious approach. The initial amount prescribed may be adjusted based on the status of a patient's kidney function, which is an important consideration.

Q: Are there any long-term effects associated with taking Enalten?

A: Enalten is indicated for chronic (long-term) conditions, and studies show its blood pressure-lowering effect is maintained over extended periods of time. The safety profile is defined in regulatory documents and outlines the necessity of monitoring for serious, systemic effects.

Q: How often is Enalten usually taken?

A: For most adult indications, regulatory dosing schedules typically describe taking Enalten once a day. However, for specific medical conditions, such as heart failure, the dose may be officially described as being administered twice a day.

Q: Is it safe to drive while taking Enalten?

A: Official patient information states that Enalten can cause side effects such as dizziness or blurred vision. If these effects occur, especially when starting treatment or after a dose change, regulatory information advises against driving or operating heavy machinery.

Q: Are there any dietary restrictions specifically mentioned for Enalten?

A: Official documents advise caution regarding co-administration with potassium supplements or potassium-containing salt substitutes. This is due to the potential for Enalten to cause hyperkalemia (elevated serum potassium levels).

Q: Does Enalten have any effect on blood sugar levels?

A: Government health information suggests that Enalten can sometimes lower the sugar level in the blood. For this reason, monitoring blood sugar more frequently may be needed for patients with diabetes, particularly when starting treatment.

Q: Is Enalten a steroid?

A: No. Enalten (Enalapril maleate) is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor, which targets the body's vascular system. It is a synthetic chemical compound and is not classified as a steroid.

Q: Can Enalten be taken with vitamins?

A: Regulatory guidance advises patients to inform their health professional about all other supplements they use, including vitamins and herbs. This is especially important for supplements that contain potassium, which can interact with this medicine.

Q: Is Enalten a new or established medication?

A: Enalten is considered a well-established medication. The active ingredient, Enalapril, was first approved by the U.S. Food and Drug Administration (FDA) in the 1980s.

Q: Do studies show Enalten losing effectiveness over time?

A: Official information states that the blood pressure-lowering effects of Enalapril have been observed to continue during long-term therapy and does not mention a general loss of effectiveness over time.

Q: Can Enalten cause stomach upset?

A: Official safety documents list several gastrointestinal reactions. Nausea, abdominal pain, vomiting, and diarrhea are all described as common adverse reactions in the product information.

Q: Is Enalten only for short-term use?

A: No. Enalten is approved for the management of chronic conditions like hypertension and heart failure. Clinical trials and official indications support its use for long-term therapy.

Q: Does Enalten have to be taken with food?

A: Official administration instructions clearly state that the tablets may be taken with or without food. Taking it with a meal does not affect the absorption of the medicine.

Q: Are there genetic factors that affect how Enalten works?

A: Some research on genetic factors, such as specific gene variations, has been associated with an altered risk of certain side effects, such as cough, when patients are treated with Enalapril.

Q: Is Enalten commonly prescribed in other countries?

A: Yes, Enalapril is a widely approved and marketed medication in numerous countries globally, including the United States, Canada, Australia, and many countries in the European Union.

Q: Why is Enalten used for both men and women?

A: Official indications for Enalten, such as treating high blood pressure and heart failure, are not gender-specific. It is approved for use in both adult men and women, provided they meet other eligibility requirements.

Q: Is it normal to feel a bit dizzy when starting Enalten?

A: Dizziness is a very common adverse reaction, and official patient information notes that this feeling is more likely to happen when you first start taking Enalapril or after a dose increase.

Q: What is the risk of an allergic reaction to Enalten?

A: Official warnings state that Enalten can cause hypersensitivity reactions, including the severe, potentially life-threatening reaction known as Angioedema. This involves swelling of the face, lips, tongue, glottis, and/or larynx.

Q: What is the difference between Enalten and similar medicines used for the same purpose?

A: Enalten belongs to the ACE inhibitor class, which works by affecting a specific chemical pathway in the body known as the RAAS (Renin-Angiotensin-Aldosterone System). Other medicines used for similar conditions, such as Angiotensin II Receptor Blockers (ARBs), work by targeting a different point in this same system.

Q: Is Enalten used for conditions other than the main one listed?

A: Yes. In addition to treating high blood pressure and symptomatic heart failure, official documentation notes that Enalten is also approved to treat asymptomatic left ventricular dysfunction to help decrease the rate of developing overt heart failure.

Q: What types of food or drink should be avoided while on Enalten?

A: Official documents advise caution or avoidance of potassium-containing salt substitutes or potassium supplements. This is due to the potential for the medicine to increase potassium levels in the blood.

Q: Does Enalten interact with herbal supplements?

A: Regulatory guidance advises patients to inform their health professional about all other products and supplements they use, including herbal supplements, to assess any potential for interaction.

Q: Are there any known drug-disease interactions for Enalten (besides liver/kidney)?

A: Yes. Key restrictions are noted for patients with a history of angioedema related to any previous ACE inhibitor use, and for patients undergoing dialysis with certain high-flux membranes.

Q: Can Enalten cause mood changes or depression?

A: Official safety data lists depression as a common adverse reaction associated with the use of Enalten. Less commonly, nervousness and dream abnormalities have also been reported.

Q: What is the potential for Enalten to interact with grapefruit juice?

A: Published pharmacological reviews indicate that, unlike some other drug classes, Enalapril has generally not shown an interaction with grapefruit juice.

How should Enalten be stored and disposed of?

How to Store and Dispose of Enalten?

The storage and disposal of Enalten (Enalapril maleate) tablets must strictly follow regulatory documentation to maintain stability and ensure environmental safety.


Storage Requirements

Enalten must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and protected from moisture. To ensure stability, the tablets must be stored in the original container and the container must remain tightly closed.

As a mandatory safety measure, Enalten must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Enalten should be disposed of in accordance with local and national regulations for pharmaceutical waste. The medicine must not be flushed down the toilet, poured down a drain, or otherwise allowed to enter the sewage or water system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enalten found in:

A-Z Index: